Armistice Capital LLC Has $21.75 Million Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Armistice Capital LLC grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 33.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,250,000 shares of the company's stock after purchasing an additional 1,578,000 shares during the period. Armistice Capital LLC owned approximately 2.35% of Autolus Therapeutics worth $21,750,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of AUTL. ProShare Advisors LLC bought a new position in Autolus Therapeutics in the second quarter valued at about $43,000. Daiwa Securities Group Inc. increased its position in Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics in the first quarter valued at approximately $100,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Autolus Therapeutics during the first quarter worth $108,000. Finally, SG Americas Securities LLC acquired a new position in shares of Autolus Therapeutics during the first quarter worth $127,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Trading Up 0.9 %

NASDAQ AUTL traded up $0.03 on Thursday, reaching $3.48. The company had a trading volume of 490,579 shares, compared to its average volume of 1,393,190. The firm has a market cap of $925.99 million, a price-to-earnings ratio of -2.87 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. Autolus Therapeutics plc has a fifty-two week low of $2.01 and a fifty-two week high of $7.45. The business has a 50 day moving average of $4.03 and a two-hundred day moving average of $4.35.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AUTL shares. Needham & Company LLC reissued a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a report on Monday, June 17th. William Blair restated an "outperform" rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.70.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.